Jason Loveridge has been the CEO of 4SC AG (ETR:VSC) since 2016. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap shot of the ...

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Jason Loveridge has been the CEO of 4SC AG (ETR:VSC) since 2016. First, this ...

We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly. Zooming in on an example, the 4SC AG (ETR:VSC) share price dropped 55% in the last ...

We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. Zooming in on an example, the 4SC AG (ETR:VSC) share price dropped 60% in the ...

4SC AG has announced clinical data of the Phase I 'AEGIS' trial with the anti-cancer compound 4SC-205 in tumour patients. All primary study objectives were achieved. A comprehensive safety and ...

4SC AG has announced that it has further continued its successful development in the 2012 financial year. The consolidated financial results according to IFRS published by the Company for both the ...

Planegg-Martinsried, Germany, 19 April 2022 – 4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2022, presenting all material developments up to 31 March 2022 and the Company's ...

Planegg-Martinsried, Germany (pta007/11.09.2020/07:30 UTC+2) Maruho and 4SC agree to terminate their development agreement related to 4SC's Kv1.3 inhibitors. 4SC to reacquire all rights to the ...

German biotech 4SC has filed its oral HDAC inhibitor Kinselby with the EMA, hoping to provide a much-needed new therapy for patients with the rare cancer cutaneous T-Cell lymphoma (CTCL). CTCL is a ...

PLANEGG-MARTINSRIED, Germany & TOKYO--(BUSINESS WIRE)--4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an exclusive license by 4SC to ...

- Resminostat/sorafenib combination therapy halts further disease progression in two thirds of patients (PFSR 66.6%) and achieves median progression-free survival (PFS) of 4.6 months - First ...